189 related articles for article (PubMed ID: 21423646)
1. BCG-mediated protection against Mycobacterium ulcerans infection in the mouse.
Converse PJ; Almeida DV; Nuermberger EL; Grosset JH
PLoS Negl Trop Dis; 2011 Mar; 5(3):e985. PubMed ID: 21423646
[TBL] [Abstract][Full Text] [Related]
2. Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination.
Fraga AG; Martins TG; Torrado E; Huygen K; Portaels F; Silva MT; Castro AG; Pedrosa J
PLoS One; 2012; 7(3):e33406. PubMed ID: 22413022
[TBL] [Abstract][Full Text] [Related]
3. Recombinant BCG Expressing Mycobacterium ulcerans Ag85A Imparts Enhanced Protection against Experimental Buruli ulcer.
Hart BE; Hale LP; Lee S
PLoS Negl Trop Dis; 2015 Sep; 9(9):e0004046. PubMed ID: 26393347
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine Efficacy.
Hart BE; Lee S
PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005229. PubMed ID: 27941982
[TBL] [Abstract][Full Text] [Related]
5. Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model.
Mangas KM; Buultjens AH; Porter JL; Baines SL; Marion E; Marsollier L; Tobias NJ; Pidot SJ; Quinn KM; Price DJ; Kedzierska K; Zeng W; Jackson DC; Chua BY; Stinear TP
Infect Immun; 2020 Feb; 88(3):. PubMed ID: 31818964
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of a dewaxed whole-cell vaccine against Mycobacterium ulcerans infection in mice.
Watanabe M; Nakamura H; Nabekura R; Shinoda N; Suzuki E; Saito H
Vaccine; 2015 May; 33(19):2232-2239. PubMed ID: 25825332
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the vaccine potential of plasmid DNA encoding nine mycolactone polyketide synthase domains in Mycobacterium ulcerans infected mice.
Roupie V; Pidot SJ; Einarsdottir T; Van Den Poel C; Jurion F; Stinear TP; Huygen K
PLoS Negl Trop Dis; 2014; 8(1):e2604. PubMed ID: 24392169
[TBL] [Abstract][Full Text] [Related]
8. A booster vaccination with Mycobacterium bovis BCG does not increase the protective effect of the vaccine against experimental Mycobacterium ulcerans infection in mice.
Tanghe A; Adnet PY; Gartner T; Huygen K
Infect Immun; 2007 May; 75(5):2642-4. PubMed ID: 17325046
[TBL] [Abstract][Full Text] [Related]
9. Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer.
Tanghe A; Content J; Van Vooren JP; Portaels F; Huygen K
Infect Immun; 2001 Sep; 69(9):5403-11. PubMed ID: 11500410
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with the Surface Proteins MUL_2232 and MUL_3720 of Mycobacterium ulcerans Induces Antibodies but Fails to Provide Protection against Buruli Ulcer.
Bolz M; Bénard A; Dreyer AM; Kerber S; Vettiger A; Oehlmann W; Singh M; Duthie MS; Pluschke G
PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004431. PubMed ID: 26849213
[TBL] [Abstract][Full Text] [Related]
11. Cross-reactive immune responses against Mycobacterium bovis BCG in mice infected with non-tuberculous mycobacteria belonging to the MAIS-Group.
Lozes E; Denis O; Drowart A; Jurion F; Palfliet K; Vanonckelen A; De Bruyn J; De Cock M; Van Vooren JP; Huygen K
Scand J Immunol; 1997 Jul; 46(1):16-26. PubMed ID: 9246204
[TBL] [Abstract][Full Text] [Related]
12. Systematic review of M. Bovis BCG and other candidate vaccines for Buruli ulcer prophylaxis.
Muhi S; Stinear TP
Vaccine; 2021 Dec; 39(50):7238-7252. PubMed ID: 34119347
[TBL] [Abstract][Full Text] [Related]
13. Mycobacterium ulcerans-specific immune response after immunisation with bacillus Calmette-Guérin (BCG) vaccine.
Pittet LF; Tebruegge M; Dutta B; Donath S; Messina N; Casalaz D; Hanekom WA; Britton WJ; Robins-Browne R; Curtis N; Ritz N;
Vaccine; 2021 Jan; 39(4):652-657. PubMed ID: 33371993
[TBL] [Abstract][Full Text] [Related]
14.
Jia Q; Masleša-Galić S; Nava S; Horwitz MA
mBio; 2022 Jun; 13(3):e0068722. PubMed ID: 35642945
[TBL] [Abstract][Full Text] [Related]
15. Assessment of different formulations of oral Mycobacterium bovis Bacille Calmette-Guérin (BCG) vaccine in rodent models for immunogenicity and protection against aerosol challenge with M. bovis.
Clark S; Cross ML; Smith A; Court P; Vipond J; Nadian A; Hewinson RG; Batchelor HK; Perrie Y; Williams A; Aldwell FE; Chambers MA
Vaccine; 2008 Oct; 26(46):5791-7. PubMed ID: 18789366
[TBL] [Abstract][Full Text] [Related]
16. FVB/N Mice Spontaneously Heal Ulcerative Lesions Induced by Mycobacterium ulcerans and Switch M. ulcerans into a Low Mycolactone Producer.
Marion E; Jarry U; Cano C; Savary C; Beauvillain C; Robbe-Saule M; Preisser L; Altare F; Delneste Y; Jeannin P; Marsollier L
J Immunol; 2016 Mar; 196(6):2690-8. PubMed ID: 26873988
[TBL] [Abstract][Full Text] [Related]
17. Mycobacterium ulcerans Mouse Model Refinement for Pre-Clinical Profiling of Vaccine Candidates.
Bénard A; Sala C; Pluschke G
PLoS One; 2016; 11(11):e0167059. PubMed ID: 27893778
[TBL] [Abstract][Full Text] [Related]
18. Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease.
Portaels F; Aguiar J; Debacker M; Guédénon A; Steunou C; Zinsou C; Meyers WM
Infect Immun; 2004 Jan; 72(1):62-5. PubMed ID: 14688081
[TBL] [Abstract][Full Text] [Related]
19. A DNA prime-live vaccine boost strategy in mice can augment IFN-gamma responses to mycobacterial antigens but does not increase the protective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculosis.
Skinner MA; Ramsay AJ; Buchan GS; Keen DL; Ranasinghe C; Slobbe L; Collins DM; de Lisle GW; Buddle BM
Immunology; 2003 Apr; 108(4):548-55. PubMed ID: 12667217
[TBL] [Abstract][Full Text] [Related]
20. Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting.
Tanghe A; Dangy JP; Pluschke G; Huygen K
PLoS Negl Trop Dis; 2008 Mar; 2(3):e199. PubMed ID: 18350112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
